Five things for pharma marketers to know: Monday, February 13, 2016
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
Opioids
Five things for pharma marketers to know: Tuesday, January 10, 2017
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet’s opioid Arymo ER gets FDA approval
Five things for pharma marketers to know: Thursday, December 15, 2016
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
Five things for pharma marketers to know: Thursday, October 20, 2016
Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug
Five things for pharma marketers to know: Friday, September 30, 2016
Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit
Five things for pharma marketers to know: Monday, September 19, 2016
Some U.S. hospitals still haven’t received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
The FDA warns drugmakers over promotion of experimental opioid
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
Five things for pharma marketers to know: Tuesday, August 23, 2016
Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer’s opioid
Five things for pharma marketers to know: Tuesday, August 16, 2016
OncoGenex’s prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
Five things for pharma marketers to know: Tuesday, August 2, 2016
IBM develops chip to detect early stages of cancer; Theranos plans to develop a “minilab;” Aetna and Humana to sell $117 million in assets
